Dendreon Announces Collaboration with The R.W. Johnson Pharmaceutical Research Institute in Development of Immunotherapy for Cancer.Business Editors/Health & Medical Writers SEATTLE--(BW HealthWire)--Oct. 11, 2000 leader in cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine to advance research and development activities Dendreon Corporation (Nasdaq:DNDN) today announced the signing of a strategic collaboration agreement for the advancement of cancer immunotherapies with The R.W. Johnson Pharmaceutical Research Institute (PRI PRI: see Institutional Revolutionary party. (Primary Rate Interface) An ISDN service that provides 23 64 Kbps B (Bearer) channels and one 64 Kbps D (Data) channel (23B+D), which is equivalent to the 24 channels of a T1 line. ), a member of the Johnson & Johnson family of companies (NYSE NYSE See: New York Stock Exchange :JNJ JNJ Johnson and Johnson (stock symbol) JNJ Journal of Nursing Jocularity ). The collaboration will provide the opportunity for Dendreon and PRI to use each other's products and technologies to develop optimal immunotherapies, including dendritic dendritic /den·drit·ic/ (den-drit´ik) 1. branched like a tree. 2. pertaining to or possessing dendrites. den·drit·ic adj. Relating to the dendrites of nerve cells. cell-based vaccine therapy vaccine therapy A therapeutic strategy to boost the immune response against a particular pathogen to such degree that the vaccine alone is enough to treat the Pt for the treatment of a variety of cancers, including breast, ovarian and colorectal cancers. The collaboration will also involve the use of products and technologies that may be developed by the companies. "PRI is a strong partner for Dendreon Corporation," said David Urdal, Ph.D., Chief Scientific Officer of Dendreon. "PRI's innovation in biotechnology, coupled with Dendreon's leadership in the cancer immunotherapy arena, provides a significant validation for this important area of clinical development and a strong groundwork for our future research and development activities." Under the terms of the agreement, PRI will provide financial support for research and development activities to be carried out by Dendreon. Dendreon will also be responsible for clinical testing. Immunotherapy treatments aim to harness the natural power of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to fight against diseases such as cancer. Avoiding the harsh side effects Side effects Effects of a proposed project on other parts of the firm. associated with other forms of treatment, immunotherapies may offer new hope to patients. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. Dendreon is focused on the development of therapeutic cancer vaccines through the use of antigen discovery, antigen engineering and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. technologies. Dendreon's vaccine for the treatment of prostate cancer, Provenge(TM), is in Phase III clinical trials and its vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in Phase II clinical trials. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing our clinical trials, and dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's SEC Reports, including Dendreon's Form 10-Q and Form S-1 Registration Statement, No. 333-31920, which are available at www.sec.gov. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion